Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

• Published in: The lancet oncology 2023-06, Vol.24 (6), p.597-610
• Main Authors: Fizazi, Karim, Herrmann, Ken, Krause, Bernd J, Rahbar, Kambiz, Chi, Kim N, Morris, Michael J, Sartor, Oliver, Tagawa, Scott T, Kendi, Ayse T, Vogelzang, Nicholas, Calais, Jeremie, Nagarajah, James, Wei, Xiao X, Koshkin, Vadim S, Beauregard, Jean-Mathieu, Chang, Brian, Ghouse, Ray, DeSilvio, Michelle, Messmann, Richard A, de Bono, Johann
• Format: Article
• Language: English
• Subjects: Adverse events; Aged; Androgen Receptor Antagonists - adverse effects; Androgen receptors; Androgens; Antigens; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bisphosphonates; Blood; Bone marrow; Brain; Cancer therapies; Castration; Chemotherapy; Dura mater; Hematology; Hematoma; Hemoglobin; Hemorrhage; Humans; L-Lactate dehydrogenase; Lymphocytes; Male; Meninges; Metastases; Metastasis; Mortality; Pain; Pain - chemically induced; Pancytopenia; Patients; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Quality of Life; Radiation; Radiation therapy; Receptors, Androgen; Scintigraphy; Standard of Care; Taxanes; Taxoids
• ISSN: 1470-2045; 1474-5488
• DOI: 10.1016/S1470-2045(23)00158-4

In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) improved radiographic progression-free survival and overall survival when added to protocol-permitted standard of care in patients with metastatic castration-resistant prostate cancer. Here, we report additional health-related quality of life (HRQOL), pain, and symptomatic skeletal event results. This multicentre, open-label, randomised, phase 3 trial was conducted at 84 cancer centres in nine countries in North America and Europe. Eligible patients were aged 18 years or older; had progressive PSMA-positive metastatic castration-resistant prostate cancer; an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2; and had previously received of at least one androgen receptor pathway inhibitor and one or two taxane-containing regimens. Patients were randomly assigned (2:1) to receive either [177Lu]Lu-PSMA-617 plus protocol-permitted standard of care ([177Lu]Lu-PSMA-617 group) or standard of care alone (control group) using permuted blocks. Randomisation was stratified by baseline lactate dehydrogenase concentration, liver metastases, ECOG performance status, and androgen receptor pathway inhibitor inclusion in standard of care. Patients in the [177Lu]Lu-PSMA-617 group received intravenous infusions of 7·4 gigabecquerel (GBq; 200 millicurie [mCi]) [177Lu]Lu-PSMA-617 every 6 weeks for four cycles plus two optional additional cycles. Standard of care included approved hormonal treatments, bisphosphonates, and radiotherapy. The alternate primary endpoints were radiographic progression-free survival and overall survival, which have been reported. Here we report the key secondary endpoint of time to first symptomatic skeletal event, and other secondary endpoints of HRQOL assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D-5L, and pain assessed with the Brief Pain Inventory-Short Form (BPI-SF). Patient-reported outcomes and symptomatic skeletal events were analysed in all patients who were randomly assigned after implementation of measures designed to reduce the dropout rate in the control group (on or after March 5, 2019), and safety was analysed according to treatment received in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, NCT03511664, and is active but not recruiting. Between June 4, 2018, and Oct 23, 2019,